The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells

详细信息    查看全文

• 作者：Si Hyoung Kim ; Jun Goo Kang ; Chul Sik Kim ; Sung-Hee Ihm ; Moon Gi Choi…
• 关键词：Anaplastic thyroid carcinoma ; SNX5422 ; HDAC inhibitor ; Synergism ; Akt
• 刊名：Endocrine
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：51
• 期：2
• 页码：274-282
• 全文大小：1,647 KB
• 参考文献：1.N. Smith, C. Nucera, Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J. Clin. Endocrinol. Metab. 100, 35–42 (2015)PubMedCentral CrossRef PubMed
  2.L.H. Pearl, C. Prodromou, Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75, 271–294 (2006)CrossRef PubMed
  3.Y.S. Kim, S.V. Alarcon, S. Lee, M.J. Lee, G. Giaccone, L. Neckers, J.B. Trepel, Update on Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem. 9, 1479–1492 (2009)CrossRef PubMed
  4.S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells. Endocrine 48, 886–893 (2015)CrossRef PubMed
  5.S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, The novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 100, E253–E261 (2015)CrossRef PubMed
  6.S.H. Kim, J.G. Kang, C.S. Kim, S.-H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Hsp70 inhibition potentiates radicicol-induced cell death in anaplastic thyroid carcinoma cells. Anticancer Res. 34, 4829–4837 (2014)PubMed
  7.S.X. Wang, H.Q. Ju, K.S. Liu, J.X. Zhang, X. Wang, Y.F. Xiang, R. Wang, J.Y. Liu, Q.Y. Liu, M. Xia, G.W. Xing, Z. Liu, Y.F. Wang, SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. Biosci. Biotechnol. Biochem. 75, 1540–1545 (2011)CrossRef PubMed
  8.K.H. Huang, J.M. Veal, R.P. Fadden, J.W. Rice, J. Eaves, J.P. Strachan, A.F. Barabasz, B.E. Foley, T.E. Barta, W. Ma, M.A. Silinski, M. Hu, J.M. Partridge, A. Scott, L.G. DuBois, T. Freed, P.M. Steed, A.J. Ommen, E.F. Smith, P.F. Hughes, A.R. Woodward, G.J. Hanson, W.S. McCall, C.J. Markworth, L. Hinkley, M. Jenks, L. Geng, M. Lewis, J. Otto, B. Pronk, K. Verleysen, S.E. Hall, Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J. Med. Chem. 52, 4288–4305 (2009)CrossRef PubMed
  9.P. Fadden, K.H. Huang, J.M. Veal, P.M. Steed, A.F. Barabasz, B. Foley, M. Hu, J.M. Partridge, J. Rice, A. Scott, L.G. Dubois, T.A. Freed, M.A. Silinski, T.E. Barta, P.F. Hughes, A. Ommen, W. Ma, E.D. Smith, A.W. Spangenberg, J. Eaves, G.J. Hanson, L. Hinkley, M. Jenks, M. Lewis, J. Otto, G.J. Pronk, K. Verleysen, T.A. Haystead, S.E. Hall, Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem. Biol. 17, 686–694 (2010)CrossRef PubMed
  10.A. Rajan, R.J. Kelly, J.B. Trepel, Y.S. Kim, S.V. Alarcon, S. Kummar, M. Gutierrez, S. Crandon, W.M. Zein, L. Jain, B. Mannargudi, W.D. Figg, B.E. Houk, M. Shnaidman, N. Brega, G. Giaccone, A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin. Cancer Res. 17, 6831–6839 (2011)PubMedCentral CrossRef PubMed
  11.J.R. Infante, G.J. Weiss, S. Jones, R. Tibes, T.M. Bauer, J.C. Bendell, J.M. Hinson, D.D. Von Hoff, Jr., H.A. Burris, III, E.O. Orlemans, R.K. Ramanathan, Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. Eur. J. Cancer 50, 2897–2904 (2014)
  12.N. Reddy, P.M. Voorhees, B.E. Houk, N. Brega, J.M. Hinson Jr, A. Jillela, Phase I trial of the hsp90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. Cl. Lymph. Myelom. Leuk. 13, 385–391 (2013)CrossRef
  13.P.A. Marks, M. Dokmanovic, Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497–1511 (2005)CrossRef PubMed
  14.S.F. Lin, J.D. Lin, T.C. Chou, Y.Y. Huang, R.J. Wong, Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS ONE 8, e77684 (2013)PubMedCentral CrossRef PubMed
  15.Q.T. Luong, J. O’Kelly, G.D. Braunstein, J.M. Hershman, H.P. Koeffler, Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin. Cancer Res. 12, 5570–5577 (2006)CrossRef PubMed
  16.M.G. Catalano, N. Fortunati, M. Pugliese, R. Poli, O. Bosco, R. Mastrocola, M. Aragno, G. Boccuzzi, Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol. 191, 465–472 (2006)CrossRef PubMed
  17.M.G. Catalano, R. Poli, M. Pugliese, N. Fortunati, G. Boccuzzi, Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr. Relat. Cancer 14, 839–845 (2007)CrossRef PubMed
  18.P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, E. Seto, K. Bhalla, Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729–26734 (2005)CrossRef PubMed
  19.M. Baritaud, L. Cabon, L. Delavallee, P. Galan-Malo, M.E. Gilles, M.N. Brunelle-Navas, S.A. Susin, AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced histone H2AX Ser139 phosphorylation. Cell Death Dis. 3, e390 (2012)PubMedCentral CrossRef PubMed
  20.K. Flatten, N.T. Dai, B.T. Vroman, D. Loegering, C. Erlichman, L.M. Karnitz, S.H. Kaufmann, The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. J. Biol. Chem. 280, 14349–14355 (2005)CrossRef PubMed
  21.K. Ha, W. Fiskus, R. Rao, R. Balusu, S. Venkannagari, N.R. Nalabothula, K.N. Bhalla, Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Mol. Cancer Ther. 10, 1194–1206 (2011)CrossRef PubMed
  22.P. Fortugno, E. Beltrami, J. Plescia, J. Fontana, D. Pradhan, P.C. Marchisio, W.C. Sessa, D.C. Altieri, Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. U.S.A. 100, 13791–13796 (2003)PubMedCentral CrossRef PubMed
  23.D.C. Altieri, Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 430, 199–205 (2010)PubMedCentral CrossRef PubMed
  24.J. Tran, Z. Master, J.L. Yu, J. Rak, D.J. Dumont, R.S. Kerbel, A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. U.S.A. 99, 4349–4354 (2002)PubMedCentral CrossRef PubMed
  25.M. Zhang, D.E. Latham, M.A. Delaney, A. Chakravarti, Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24, 2474–2482 (2005)CrossRef PubMed
  26.M. Hwang, L. Moretti, B. Lu, HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr. Med. Chem. 16, 3081–3092 (2009)CrossRef PubMed
  27.M. Xing, Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 13, 184–199 (2013)PubMedCentral CrossRef PubMed
  28.G. Pannone, A. Santoro, D. Pasquali, R. Zamparese, M. Mattoni, G.M. Russo, M. Landriscina, A. Piscazzi, P. Toti, M. Cignarelli, L. Lo, Muzio, P. Bufo, The role of survivin in thyroid tumors: differences of expression in well differentiated (Wdtc), non-well differentiated (Non-Wdtc) and anaplastic (Atc) thyroid cancers. Thyroid 24, 511–519 (2014)CrossRef PubMed
  
• 作者单位：Si Hyoung Kim (1)
  Jun Goo Kang (1)
  Chul Sik Kim (1)
  Sung-Hee Ihm (1)
  Moon Gi Choi (1)
  Hyung Joon Yoo (1)
  Seong Jin Lee (1)
  
  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea
  
• 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, general;
• 出版者：Springer US
• ISSN：1559-0100

文摘

The influence of the heat shock protein 90 (hsp90) inhibitor SNX5422 alone or in combination with the histone deacetylase (HDAC) inhibitors PXD101, suberoylanilide hydroxamic acid (SAHA), and trichostatin A (TSA) on survival of anaplastic thyroid carcinoma (ATC) cells was investigated. In 8505C and CAL62 cells, SNX5422 caused cell death with concomitant changes in the expression of hsp90 client proteins. After treatment of both SNX5422 and PXD101, SAHA and TSA, compared with treatment of SNX5422 alone, cell viability was diminished, whereas inhibition rate and cytotoxic activity were enhanced. All of the combination index values were lower than 1.0, suggesting the synergism between SNX5422 and PXD101, SAHA and TSA in induction of cell death. In cells treated with both SNX5422 and PXD101, SAHA and TSA, compared with cells treated with SNX5422 alone, the protein levels of Akt, phospho-4EBP1, phospho-S6 K, and survivin were diminished, while those of γH2AX, acetyl. histone H3, acetyl. histone H4, cleaved PARP, and cleaved caspase-3 were enhanced. In conclusion, these results demonstrate that SNX5422 has a cytotoxic activity in conjunction with alterations in the expression of hsp90 client proteins in ATC cells. Moreover, SNX5422 synergizes with HDAC inhibitors in induction of cytotoxicity accompanied by the suppression of PI3K/Akt/mTOR signaling and survivin, and the overexpression of DNA damage-related proteins in ATC cells. Keywords Anaplastic thyroid carcinoma SNX5422 HDAC inhibitor Synergism Akt